Lv6
1894 积分 2022-12-14 加入
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
1个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in advanced squamous non-small-cell lung cancer (HARMONi-6): interim overall survival analysis of a randomised, double-blind, phase 3 trial in China
1个月前
已完结
Neoadjuvant disitamab vedotin plus carboplatin in patients with HER2-expressing ovarian cancer: A prospective, single-arm, phase II trial
1个月前
已关闭
SACITUZUMAB TIRUMOTECAN MONOTHERAPY IN ADVANCED/METASTATIC ENDOMETRIAL CARCINOMA: RESULTS FROM A PHASE 1/2 STUDY (2870-001/KL264-01)
2个月前
已关闭
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
2个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
2个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
2个月前
已完结
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
2个月前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
2个月前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
2个月前
已完结
皖公网安备34019202002308
